Skip to main content
Publications
Accordini S, Calciano L, Marcon A, Pesce G, Anto JM, Beckmeyer-Borowko AB, Carsin AE, Corsico AG, Imboden M, Janson C, Keidel D, Locatelli F, Svanes C, Burney PGJ, Jarvis D, Probst-Hensch NM, Minelli C. Incidence trends of airflow obstruction among European adults without asthma: a 20-year cohort study. Sci Rep. 2020 Feb 26;10(1):3452. doi: 10.1038/s41598-020-60478-5
Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Twiss J, Whalley D, Doward L, Balp MM, Brass C, Lopez P, Loeffler J, Cai J, Cryer D, Sanyal AJ, Anstee QM. Psychometric evaluation of NASH-CHECK, a patient-reported outcome measure for Nonalcoholic Steatohepatitis. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Steward T, Mestre-Bach G, Granero R, Sanchez I, Riesco N, Vintro-Alcaraz C, Sauchelli S, Jimenez-Murcia S, Aguera Z, Fernandez-Garcia JC, Garrido-Sanchez L, Tinahones FJ, Casanueva FF, Banos RM, Botella C, Crujeiras AB, Torre R, Fernandez-Real JM, Fruhbeck G, Ortega FJ, Rodriguez A, Menchon JM, Fernandez-Aranda F. Reduced plasma orexin-A concentrations are associated with cognitive deficits in anorexia nervosa. Sci Rep. 2019 May 27;9(1):7910. doi: 10.1038/s41598-019-44450-6
Herring W, Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Herring W, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Trantham L, Klein AB, Parikh RC, Kurosky S, Zhang Y, Levine CA, Kaye JA. Unresectable, locally advanced, stage III non-small cell lung cancer: real-world clinical characteristics, treatment patterns, and health care resource utilization in Europe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49. doi: 10.1016/j.jval.2018.04.289